```html

Human Immunodeficiency Virus (HIV) – Comprehensive Medical Guide

Overview

Human immunodeficiency virus (HIV) is a lentivirus that attacks the body’s immune system, specifically CD4‑positive T‑lymphocytes (helper T cells). Over time, the virus can destroy enough of these cells that the body can no longer fight off common infections and certain cancers, leading to acquired immunodeficiency syndrome (AIDS).

Who it affects: HIV does not discriminate by age, gender, race, or sexual orientation. However, epidemiologic data show higher prevalence among men who have sex with men (MSM), people who inject drugs, sex workers, and certain geographic regions.

Prevalence (2023 estimates):

• Globally, ~38.4 million people are living with HIV (UNAIDS, 2023).
• Approximately 1.5 million new infections occurred worldwide in 2022.
• In the United States, ~1.2 million people are living with HIV; ~13% are unaware of their infection.

Symptoms

Symptoms vary widely depending on the stage of infection. Early infection may be asymptomatic, while advanced disease can involve opportunistic infections.

Acute HIV Infection (2‑4 weeks after exposure)

• Fever – often the first sign.
• Rash – usually a maculopapular rash on the trunk.
• Sore throat and swollen lymph nodes (especially in the neck).
• Muscle aches and headache.
• Fatigue and night sweats.
• Occasional diarrhea and vomiting.

Clinical Latency (Chronic HIV)

• Often no symptoms for years; the virus quietly replicates.
• Gradual weight loss or “wasting” may appear.
• Persistent swollen lymph nodes, especially in the armpits.
• Recurrent oral thrush, skin rashes, or herpes zoster (shingles).

AIDS‑defining Illnesses (CD4 count < 200 cells/µL)

• Pneumocystis jirovecii pneumonia (PCP) – fever, dry cough, shortness of breath.
• Mycobacterium avium complex (MAC) – fever, night sweats, weight loss.
• Kaposi sarcoma – purple or red skin lesions.
• Non‑Hodgkin lymphoma, primary CNS lymphoma.
• Cytomegalovirus (CMV) retinitis – vision changes, floaters.
• Cryptococcal meningitis – severe headache, neck stiffness.

Causes and Risk Factors

How HIV Is Transmitted

• Sexual contact – unprotected vaginal, anal, or oral sex with an infected partner.
• Blood exposure – sharing needles, syringe reuse, or transfusion of contaminated blood (rare in countries with screened blood supplies).
• Mother‑to‑child – during pregnancy, childbirth, or breastfeeding.

Primary Risk Factors

• Having multiple sexual partners or a partner with unknown HIV status.
• Engaging in unprotected anal intercourse (higher risk than vaginal).
• Injection drug use or using non‑sterile tattooing/piercing equipment.
• Having another sexually transmitted infection (STI) – ulcers increase entry points.
• Men who have sex with men (MSM) – higher prevalence in many regions.
• Geographic location – Sub‑Saharan Africa accounts for ~67% of global infections.

Diagnosis

Screening Tests

• Fourth‑generation antigen/antibody laboratory test – detects both HIV‑1/2 antibodies and p24 antigen; can identify infection as early as 2‑4 weeks after exposure.
• Rapid point‑of‑care tests – finger‑stick or oral swab; results in 20‑30 minutes, usually antibody‑only.
• CDC recommends routine screening for all individuals aged 13‑64 at least once, and annually for those with ongoing risk.

Confirmatory Tests

• HIV‑1/HIV‑2 differentiation assay – distinguishes between HIV‑1 and HIV‑2 after a reactive screening test.
• RNA PCR (viral load) – detects viral RNA; used when recent exposure is suspected but antibody tests are negative.

Baseline Staging (after diagnosis)

• CD4+ T‑cell count – gauges immune function; ART is recommended for all, regardless of count.
• HIV viral load – quantity of virus in blood; guides treatment efficacy.
• Screening for co‑infections (hepatitis B/C, TB, syphilis) and baseline labs (CBC, renal & liver function).

Treatment Options

Antiretroviral Therapy (ART)

Current guidelines (WHO, DHHS 2024) recommend a combination of at least three drugs from two different classes. The most common first‑line regimens include:

• Integrase strand transfer inhibitor (INSTI) + two nucleoside reverse transcriptase inhibitors (NRTIs) – e.g., bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy).
• Non‑nucleoside reverse transcriptase inhibitor (NNRTI) + two NRTIs – e.g., efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).

ART is lifelong; adherence >95% is essential to achieve and maintain an undetectable viral load, which eliminates sexual transmission risk (“U=U”).

Adjunctive Therapies

• Prophylaxis for opportunistic infections – e.g., trimethoprim‑sulfamethoxazole for Pneumocystis pneumonia when CD4 <200.
• Vaccinations – annual flu, hepatitis A/B, HPV, pneumococcal, COVID‑19.
• Management of comorbidities – hypertension, diabetes, dyslipidemia, mental health.

Lifestyle Modifications

• Balanced nutrition rich in fruits, vegetables, lean protein, and whole grains.
• Regular aerobic exercise (150 min/week) improves immune health.
• Avoid smoking and limit alcohol; both can worsen ART side effects.
• Maintain a stable sleep schedule (7‑9 h/night).

Living with Human Immunodeficiency Virus Infection (HIV)

Daily Management Tips

1. Medication routine – take ART at the same time each day; use pillboxes or phone alarms.
2. Monitor labs – schedule viral load and CD4 checks every 3‑6 months, or as directed.
3. Know your numbers – an undetectable viral load (<50 copies/mL) means treatment is working.
4. Stay connected – join support groups (local AIDS service organizations, online forums) for emotional support.
5. Disclose wisely – share status with trusted partners and healthcare providers to ensure safe care.
6. Plan for emergencies – keep a copy of your ART regimen, a list of allergies, and an emergency contact card.

Mental Health & Stigma

Depression, anxiety, and substance‑use disorders are common. Access counseling, cognitive‑behavioral therapy, or medication when needed. Combat stigma by educating friends and family and using reputable resources (e.g., AIDS.gov).

Prevention

• Pre‑exposure prophylaxis (PrEP) – daily oral tenofovir/emtricitabine reduces acquisition risk by >90% for high‑risk individuals.
• Post‑exposure prophylaxis (PEP) – start within 72 h of possible exposure; continue for 28 days.
• Consistent and correct use of condoms (male or female).
• Never share needles or drug‑paraphernalia; use sterile equipment.
• For pregnant women with HIV, initiate ART early to achieve viral suppression and prevent mother‑to‑child transmission (MTCT rate <1% with optimal care).
• Routine screening for STIs and prompt treatment.

Complications

If HIV remains untreated or inadequately controlled, the immune system deteriorates, leading to:

• Opportunistic infections – PCP, CMV, cryptococcal meningitis, disseminated TB.
• Acquired immunodeficiency syndrome (AIDS) – defined by CD4 <200 cells/µL or AIDS‑defining illness.
• Cancers – Kaposi sarcoma, invasive cervical cancer, non‑Hodgkin lymphoma.
• Neurologic disorders – HIV‑associated neurocognitive disorder (HAND), peripheral neuropathy.
• Cardiovascular disease – accelerated atherosclerosis, myocardial infarction.
• Kidney disease – HIV‑associated nephropathy.
• Liver disease – co‑infection with hepatitis B/C or ART‑related hepatotoxicity.
• Bone loss – osteopenia/osteoporosis, especially with tenofovir.

When to Seek Emergency Care

References

1. World Health Organization. Global HIV & AIDS statistics — 2023 Fact sheet. WHO; 2023.
2. Centers for Disease Control and Prevention. HIV Basics. CDC; 2024.
3. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. DHHS; 2024.
4. Mayo Clinic. HIV/AIDS. Updated 2024.
5. Cleveland Clinic. HIV Treatment & Management. 2024.
6. UNAIDS. Global HIV & AIDS statistics — 2023 Report. 2023.

```